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Abstract
Calcineurin inhibitors exacerbate ischemic injury in transplanted kidneys, but it is not known if sirolimus protects or exacerbates 
the transplanted kidney from ischemic injury. We determined the effects of sirolimus alone or in combination with cyclosporin 
A (CsA) on oxygenated and hypoxic/reoxygenated rat proximal tubules in the following in vitro groups containing 6-9 rats per 
group: sirolimus (10, 50, 100, 250, 500, and 1000 ηg/mL); CsA (100 µg/mL); sirolimus (50 and 250 ηg/mL) + CsA (100 µg/mL); 
control; vehicle (20% ethanol). For in vivo studies, 3-week-old Wistar rats (150-250 g) were submitted to left nephrectomy and 
30-min renal artery clamping. Renal function and histological evaluation were performed 24 h and 7 days after ischemia (I) in 
five groups: sham, I, I + SRL (3 mg·kg-1·day-1, po), I + CsA (3 mg·kg-1·day-1, sc), I + SRL + CsA. Sirolimus did not injure oxy-
genated or hypoxic/reoxygenated proximal tubules and did not potentiate the tubular toxic effects of CsA. Neither drug affected 
the glomerular filtration rate (GFR) at 24 h. GFR was reduced in CsA-treated rats on day 7 (0.5 ± 0.1 mL/min) but not in rats 
receiving sirolimus + CsA (0.8 ± 0.1 mL/min) despite the reduction in renal blood flow (3.9 ± 0.5 mL/min). Acute tubular necrosis 
regeneration was similar for all groups. Sirolimus alone was not toxic and did not enhance hypoxia/reoxygenation injury or CsA 
toxicity to proximal tubules. Despite its hemodynamic effects, sirolimus protected post-ischemic kidneys against CsA toxicity.
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Cyclosporin A (CsA) is one of the mainstays of im-
munosuppression in solid organ transplantation, having 
provided significant improvement in the clinical outcome 
of organ transplantation. CsA is a calcineurin phosphatase 
inhibitor that prevents the transcription of cytokines and the 
progression of the T-cell cycle from G0 to G1 (1). Despite the 
pivotal role played by CsA in clinical transplantation, drug-
induced nephrotoxicity remains a serious clinical limitation. 
Abnormalities in renal hemodynamics, especially efferent 
arteriolar vasoconstriction, constitute the main mechanism 
of acute CsA nephrotoxicity. In addition, long-term CsA ad-
ministration can lead to chronic nephropathy, characterized 
by local inflammation and irreversible interstitial fibrosis 
(2-4). In addition to experimental drug-induced changes in 
renal hemodynamics, CsA can also cause direct tubular 
injury (5). Sirolimus (SRL) is an immunosuppressant used 
for the prevention and treatment of renal transplant rejection. 
Rather than working through the calcineurin pathway (1), 
SRL inhibits the activity of P70 S6 kinase, affecting critical 
biochemical events later in the T-cell cycle, preventing the 
progression from the G1 phase to the S phase. In addition, 
SRL blocks the T-cell proliferation induced by cytokines, 
alloantigens and mitogens. SRL is rapidly absorbed, well-
tolerated and safe. In contrast to calcineurin inhibitors, SRL 
has modest or no effects on kidney function, and its effect 
on direct tubular toxicity has not been demonstrated (1,2). 
The synergistic effects of SRL and CsA have prompted 
the investigation of this combination as an immunosup-
pressive regimen for renal transplant recipients. The use 
of SRL allows early CsA discontinuation or dose reduction, 
decreasing nephrotoxicity without increasing the risk of graft 
loss or acute rejection (6). However, other studies of kidney 
transplantation have shown that SRL may have long-term 
adverse subclinical effects or enhance the nephrotoxicity 
of full doses of CsA (7-10). In addition to drug-induced 
nephrotoxicity, kidney transplant recipients are at risk of 
developing ischemia/reperfusion injury, which can influence 
the clinical outcome and graft survival negatively. Ischemic 
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injury can be aggravated by CsA due to drug-induced 
arteriolar vasoconstriction (11). Experimental and clinical 
studies have provided conflicting results regarding the role 
of SRL in renal ischemia/reperfusion injury (11-18). Some 
experimental studies (6,15,16) and retrospective data 
have suggested that SRL impairs recovery from tubular 
injury in cases of severe ischemia/reperfusion injury (17). 
However, two randomized multicenter studies and one 
large single-center study have not confirmed this effect 
(12-14). Therefore, whether SRL exacerbates or protects 
the transplanted kidney from ischemic injury remains to be 
determined (18).
The molecular mechanisms involved in the potentially 
nephrotoxic response of tubular cells to immunosuppres-
sive drugs is poorly understood. Transcriptional profiles of 
human proximal tubular cells exposed to CsA, SRL or their 
combination have been established using oligonucleotide 
microarrays (3). Hierarchical clustering of genes implicated 
in the fibrotic processes showed a clear distinction between 
expression profiles with CsA and CsA + SRL treatments, 
especially after biological processes located at the cell 
membrane level such as ion transport or signal transduc-
tion. On the other hand, SRL modifies biological processes 
within the nucleus, more related to transcriptional activity. 
Genome-wide expression analysis suggested that CsA 
may induce an endoplasmic stress in tubular cells in vitro 
(3). More recently, Pallet et al. (3) demonstrated that CsA 
exposure in vivo is associated with up-regulation of the 
endoplasmic reticulum stress marker in kidney transplant bi-
opsies. The investigators concluded that the toxicogenomic 
study highlights the molecular interaction network that may 
contribute to the tubular response to CsA and SRL. These 
results may also offer a new working hypothesis for future 
research in the field of CsA nephrotoxicity (3).
The purpose of the present study was to evaluate the 
effects of SRL alone or in combination with CsA on oxygen-
ated and hypoxic/reoxygenated rat proximal tubules in vitro, 
as well as on renal ischemia/reperfusion injury in vivo.
 
Material and Methods
Animals
Male Wistar rats (3 weeks of age and weighing 150-
250 g) obtained from the animal facilities of the University 
of São Paulo School of Medicine, São Paulo, SP, Brazil, 
were used in all experimental procedures. The study was 
approved by the Bioethics Committee of the University of 
São Paulo School of Medicine, Brazil.
Isolation of proximal tubules
Proximal tubules were isolated using previously de-
scribed methods (19,20). Briefly, rats were anesthetized with 
sodium pentobarbital (50 mg/kg body weight, ip) and submit-
ted to laparotomy for kidney removal. Renal proximal tubules 
were isolated by collagenase digestion (Quimis Ltda., Brazil) 
and separated by Percoll gradient centrifugation (Hitachi, 
Japan). Aliquots of 6 mL (containing 1.0-1.5 mg/mL protein, 
Sigma, USA) were placed in siliconized Erlenmeyer flasks 
for 5 min at ice-cold temperature, under 95% O2 and 5% 
CO2, followed by 10 min at room temperature.
Hypoxia/reoxygenation
After the equilibration period, the isolated tubules were 
divided into experimental and control samples. Throughout 
the experiment, pO2 was maintained in the 200-300-mmHg 
range in the control group. In the experimental group, hy-
poxia (pO2: 20-40 mmHg) was induced by superfusing the 
tubules with 95% N2 and 5% CO2 for 5 min. After 15 min of 
hypoxia, the tubules were reoxygenated with 95% O2 and 
5% CO2 for 5 min. After reoxygenation, pO2 returned to the 
200-300-mmHg range. The flasks were then resealed and 
the tubules maintained under reoxygenation for 45 min. 
Samples were obtained at baseline, after hypoxia (15 min) 
and after reoxygenation (60 min).
Determination of lactate dehydrogenase
Cell injury was assessed by the release of lactate dehy-
drogenase (LDH). In order to determine LDH levels, 1 mL of 
tubule suspension was centrifuged for 60 s in a refrigerated 
centrifuge at 3500 g. The pellet was lysed with 1.5% Triton 
X-100. LDH activity was measured in the supernatant and 
pellet by the method of Bergmeyer (21). LDH activity was 
converted to percent release by dividing the supernatant 
activity by the total activity (Hitachi U2000).
Evaluation of the effects of sirolimus alone or  
combined with CsA on isolated proximal tubules
The effect of various SRL concentrations (10, 50, 100, 
250, 500, and 1000 ηg/mL) on isolated proximal tubules 
was evaluated. Subsequently, the effect of 50 and 250 ηg/
mL SRL combined with a concentration of CsA previously 
determined to be toxic (100 µg/mL) was also evaluated (5). 
The following groups were studied: control, vehicle (20% 
ethanol), SRL (10, 50, 100, 250, 500, and 1000 ηg/mL), 
CsA (100 µg/mL), and SRL + CsA (50 and 250 ηg/mL SRL 
combined with 100 µg/mL CsA).
Renal ischemia/reperfusion model
Rats were anesthetized with sodium pentobarbital (50 
mg/kg body weight, ip). An abdominal incision was made, 
and renal vessels were identified on both sides. The left 
renal pedicle was isolated and ligated, and nephrectomy 
was performed. The right renal artery was occluded with 
a microvascular clamp for 30 min; the clamp was then re-
moved in order to reestablish blood flow to the right kidney. 
The surgical incision was sutured, and rats were allowed 
to recover, with free access to food and water.
Evaluation of renal function
Renal function was evaluated by the following param-
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eters: glomerular filtration rate (GFR) measured by inulin 
clearance, serum sodium, urinary sodium, fractional excre-
tion of sodium (FENa, expressed as %), urine osmolality, 
mean arterial pressure, and renal blood flow (RBF). Rats 
were allocated to the following groups: sham = manipulation 
of the right renal pedicle plus left nephrectomy; ischemia = 
right renal artery clamping for 30 min plus left nephrectomy; 
ischemia plus SRL (I + SRL) = right renal artery clamping for 
30 min plus left nephrectomy and administration of SRL (3 
mg/kg, po); ischemia plus CsA (I + CsA) = right renal artery 
clamping for 30 min plus left nephrectomy and administra-
tion of CsA (3 mg/kg, sc); ischemia plus SRL plus CsA (I + 
SRL + CsA) = right renal artery clamping for 30 min plus 
left nephrectomy and administration of a combination of 
SRL (3 mg/kg, po) and CsA (3 mg/kg, sc).
All drugs were administered 2 days before the surgical 
procedure and maintained for 24 h (N = 6 for each group) or 
for 7 days until renal function was evaluated or the kidneys 
were removed (sham, N = 6; ischemia, N = 6; I + SRL, N = 7; 
I + CsA, N = 6; I + SRL + CsA, N = 9). All procedures were 
performed in accordance with our institutional guidelines.
For evaluation of renal function, rats were anesthetized 
with sodium pentobarbital (50 mg/kg), the trachea was 
cannulated with a polyethylene catheter (PE-240), and 
animals were maintained under spontaneous breathing. 
The jugular veins were cannulated with a PE-60 catheter 
for infusion of inulin and fluids. The right femoral artery 
was cannulated with a PE-50 catheter to monitor arterial 
pressure and for blood sampling. For urine samples, the 
urinary bladder was cannulated with a PE-240 catheter via 
a suprapubic incision. RBF was measured by a median 
incision, the left renal pedicle was carefully dissected, the 
renal artery was carefully isolated to avoid injury to renal 
nerves, an electromagnetic flow probe (Transonic Systems, 
USA) was placed around the exposed renal artery, and RBF 
was measured using an electromagnetic flowmeter (T 106 
XM; Transonic Systems). After the surgical procedure was 
completed, a loading dose of inulin (100 mg/kg diluted in 1 
mL 0.9% saline) was administered through the jugular vein, 
followed by an infusion of inulin (10 mg/kg in 0.9% saline) 
at 0.04 mL/min throughout the experimental period. Three 
urine samples were collected at 30-min intervals. Blood 
samples were collected at the beginning and at the end of 
the experiment. Inulin clearance values represent the mean 
of three periods. Blood and urine inulin were determined 
by the anthrone method (Merck KGaA, Germany), sodium 
concentration was measured using a flame photometer, 
urinary osmolality was measured using a freezing point 
(model 143; Instrumentation Laboratory, USA), and a 
fluorescence polarization immunoassay technique (PDX; 
Abbott, USA) was used to measure blood CsA.
Renal histology
All biopsy samples were fixed in Bouin’s medium for 30 
min and then immersed in 10% buffered formalin. Samples 
were processed for histology in an automatic device. 
Processing consisted of three immersions (1 h each) in 
absolute ethyl alcohol and three immersions (1 h each) 
in xylene at room temperature, followed by immersion in 
two vessels (1 h in each) containing liquid paraffin at ap-
proximately 60°C.
After embedding, the samples were blocked in paraffin 
and cut into 4-µm sections with a microtome. Sections were 
mounted on slides, deparaffinized in xylene and stained 
with hematoxylin and eosin, periodic acid-Schiff, Masson’s 
trichrome, and Jones’ silver stain. 
Histomorphometric analysis was performed to evaluate 
and quantify tubular necrosis in rat renal cortex using he-
matoxylin and eosin staining. Slides were examined under 
a light microscope (25X magnification). Examination was 
performed by a single pathologist, who was blind to the 
experimental assignments. The following histological lesions 
were considered to be indicative of tubular necrosis: loss 
of microvilli, loss of cytoplasmic and nuclear integrity, loss 
of individual tubular cells, hyaline casts filling the lumen of 
the proximal tubule, replacing lost tubular cells.
Histomorphometric analysis was performed in a blind 
manner by a single rater. The presence of acute tubular 
necrosis (ATN) was estimated in 4-µm sections stained 
with hematoxylin and eosin. Each histological parameter 
was evaluated by examining all microscopic fields (15-30 
fields in each section) at a final magnification of 250X. A 
score was attributed to each parameter, as follows: 0 = no 
lesion observed in the section; 1 = ≤25% of the section 
affected; 2 = 26-50% of the section affected; 3 = >50% of 
the section affected. 
Statistical analysis
Data are reported as means ± SD. Statistical analysis was 
performed by analysis of variance and by the Student-Newman-
Keuls post-test, with the level of significance set at P < 0.05.
Results
In vitro studies
No direct tubular toxicity was observed in isolated proxi-
mal tubules even at high SRL concentrations, up to 90 min 
of incubation (Table 1). Similarly, SRL at concentrations of 
250 ηg/mL (45.4 ± 5.9) and 500 ηg/mL (39.6 ± 3.5) did not 
enhance injury to the proximal tubules submitted to 15 min 
of hypoxia alone (40.2 ± 9.1), and all groups submitted to 
hypoxia differed from control (18.6 ± 3.5). Followed by 45 
min of reoxygenation, SRL at concentrations of 250 ηg/mL 
(54.9 ± 5.4) and 500 ηg/mL (48.8 ± 9.6) caused no significant 
injury to the proximal tubules submitted to hypoxia alone 
(53.0 ± 9.5), and all groups submitted to hypoxia differed 
from control (23.4 ± 4.4; Figure 1). 
At 60 min, the tubules treated with CsA 100 μg/mL (30.6 
± 7.3), SRL 50 + CsA 100 μg/mL (36.8 ± 10.2) and SRL 
250 + CsA 100 μg/mL (33.1 ± 3.5) presented greater LDH 
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release elevation than tubules treated with SRL alone, 50 
ηg/mL (21.0 ± 3.5) and 250 ηg/mL (21.2 ± 6.9), and control 
(21.5 ± 5.3) (Figure 2). The same effect was observed at 
90 min: CsA 100 μg/mL (49.8 ± 11.3), SRL 50 + CsA 100 
μg/mL (49.2 ± 8.5) and SRL 250 + CsA 100 μg/mL (52.0 ± 
7.6) presented greater LDH release than tubules treated 
with SRL alone, 50 ηg/mL (31.1 ± 5.6) and 250 ηg/mL (32.4 
± 7.1) and control (29.1 ± 5.9; Figure 2).
In vivo studies
At 24 h, body weight did not differ significantly among 
the experimental groups. Hematocrit was higher in the I + 
CsA group compared with the sham and ischemia groups. 
Mean arterial pressure was higher in the I + SRL + CsA 
group than in the sham group (Table 2). Despite the reduced 
RBF and increased renal vascular resistance (RVR) in all 
groups submitted to ischemia, GFR was not affected in any 
group. In addition, increased FENa was observed in I + CsA 
and I + SRL + CsA groups, and reduced urine osmolality 
was observed in the I + CsA group. Urinary volume was 
greater in the I + SRL + CsA group than in the sham group 
(P < 0.05; Table 3).
On day 7, body weight was lower in groups I + CsA and 
I + SRL + CsA than in the ischemia group. Hematocrit was 
normal and similar among groups. Mean arterial pressure 
was lower in the I + CsA group than in the sham group 
(Table 2). A significant reduction in GFR was observed 
only in the I + CsA group (P < 0.05). The decrease in GFR 
observed in the I + CsA group was not observed in the I + 
SRL + CsA group. However, SRL provided no protection 
Figure 1. Effect of sirolimus on isolated proximal tubules submit-
ted to 15 min of hypoxia (H) alone or followed by 45 min of re-
oxygenation, as assessed by release of lactate dehydrogenase 
(LDH). V = vehicle. Data are reported as mean ± SD. *P < 0.05 vs 
control at both 15 and 60 min (ANOVA followed by the Student-
Newman-Keuls post-test).
Figure 2. Effect of sirolimus combined with a toxic concentra-
tion of cyclosporin A (100 μg/mL) on isolated proximal tubules as 
assessed by lactate dehydrogenase release (LDH). SRL = siroli-
mus (ηg/mL); CsA = cyclosporin A (μg/mL). Data are reported as 
means ± SD. *P < 0.05 vs control at both 60 and 90 min (ANOVA 
followed by Student-Newman-Keuls post-test).
Table 1. Effect of sirolimus on isolated proximal tubules as assessed by lactate dehydrogenase release.
Time Control (N = 13) Vehicle (N = 8) Sirolimus (ηg/mL)
10 (N = 6) 50 (N = 9) 100 (N = 6) 250 (N = 12) 500 (N = 5) 1000 (N = 6)
Baseline 8.6 ± 2.0 9.0 ± 1.9 8.6 ± 1.1 8.5 ± 2.3 10.1 ± 1.8 9.4 ± 1.7 8.9 ± 1.7 9.5 ± 1.3
60 min 18.6 ± 3.5 19.2 ± 4.5 19.5 ± 2.5 20.4 ± 4.2 21.4 ± 9.8 20.3 ± 6.0 19.9 ± 2.8 21.8 ± 5.1
90 min 23.4 ± 4.4 26.5 ± 8.4 25.3 ± 3.8 28.2 ± 6.0 25.6 ± 4.9 30.1 ± 6.4 26.1 ± 3.0 27.6 ± 5.2
Data are reported as means ± SD lactate dehydrogenase release (%). There were no statistical differences among groups or times 
(ANOVA followed by the Student-Newman-Keuls post-test).
Effect of sirolimus and cyclosporin A on renal ischemia 741
www.bjournal.com.br Braz J Med Biol Res 43(8) 2010
against CsA-induced vasoconstriction, since both I + CsA 
and I + SRL + CsA groups showed a significant reduc-
tion in RBF and an increase in RVR. The I + SRL group 
and the sham group presented similar RBF and RVR. All 
groups submitted to ischemia, especially the I + CsA group, 
presented higher FENa. Urine osmolality was higher for 
sham, I + SRL and I + SRL + CsA groups, and reduced for 
ischemia and I + CsA groups. Urinary volume was similar 
for all groups (Table 3).
Histology
At 24 h, foci of ATN (score 2) were found in all groups. 
Table 3. Renal function and hemodynamic parameters in ischemic rats treated with sirolimus (I + SRL), cyclosporine A (I + CsA) and 
both (I + SRL + CsA).
Sham Ischemia I + SRL I + CsA I + SRL + CsA
GFR (mL/min)
24 h 0.8 ± 0.1 0.7 ± 0.2 0.9 ± 0.2 0.8 ± 0.3 0.8 ± 0.2
7 days 0.8 ± 0.1 0.7 ± 0.09 0.7 ± 0.2 0.5 ± 0.1* 0.8 ± 0.1
RBF (mL/min)
24 h 7.1 ± 0.6* 4.5 ± 0.8 4.5 ± 0.9 5.5 ± 1.0 5.1 ± 1.0
7 days 7.9 ± 0.2 7.5 ± 0.2 6.8 ± 0.7 4.4 ± 2.2*+ 3.9 ± 0.5*+
RVR (mmHg·mL-1·min-1)
24 h 16.3 ± 2.3 26.7 ± 6.8** 26.7 ± 5.8** 20.5 ± 4.8 26.2 ± 5.2**
7 days 16.1 ± 1.1 15.5 ± 1.9 18.5 ± 2.6 33.4 ± 27.2*+ 32.9 ± 6.1*+
FeNa (%)
24 h 0.8 ± 0.7 2.4 ± 1.7 2.1 ± 1.3 3.4 ± 1.4** 3.2 ± 1.9**
7 days 0.4 ± 0.4 1.3 ± 0.9 2.2 ± 1.5* 5.2 ± 3.8*+ 1.5 ± 0.4
Uosm (mmOsm/kg)
24 h 929 ± 279 606 ± 130** 838 ± 144 586 ± 313** 771 ± 163
7 days 1333 ± 424 895 ± 286* 913 ± 186* 1115 ± 325 1015 ± 274
UV (mL/min)
24 h 0.02 ± 0.01 0.04 ± 0.02 0.03 ± 0.01 0.06 ± 0.02 0.05 ± 0.02**
7 days 0.02 ± 0.01 0.03 ± 0.01 0.05 ± 0.05 0.03 ± 0.02 0.03 ± 0.03
Data are reported as means ± SD. GFR = glomerular filtration rate; RBF = renal blood flow; RVR = renal vascular resistance; FENa = 
fractional excretion of sodium; Uosm = urine osmolality; UV = urinary volume. All drugs were administered 2 days before the surgical 
procedure and maintained for 24 h or for 7 days. Doses: SRL (3 mg·kg-1·day-1, po) and CsA (3 mg·kg-1·day-1, sc). *P < 0.05 compared 
to the other groups; **P < 0.05 compared to the sham group; +P < 0.05 compared to the ischemia group (ANOVA followed by the 
Student-Newman-Keuls post-test).
Table 2. Body weight, hematocrit and mean arterial pressure (MAP) in ischemic rats treated with sirolimus (I + SRL), cyclosporine A 
(I + CsA) and both (I + SRL + CsA).
Sham Ischemia I + SRL I + CsA I + SRL + CsA
Body weight (g)
24 h 209 ± 15 209 ± 8 196 ± 28 222 ± 6 202 ± 10
7 days 230 ± 14 238 ± 13 209 ± 26 199 ± 28+ 175 ± 17+
Hematocrit (%)
24 h 43.0 ± 4.1 41.6 ± 5.8 48.3 ± 6.3 55.1 ± 10.7*+ 49.1 ± 7.6
7 days 48.3 ± 3.6 51.0 ± 2.0 47.2 ± 18 44.1 ± 7.0 48.3 ± 8.4
MAP (mmHg)
24 h 114 ± 7 118 ± 12 117 ± 9 111 ± 13 130 ± 10*
7 days 125 ± 7 117 ± 12 120 ± 15 107 ± 19* 128 ± 12
Data are reported as means ± SD. All drugs were administered 2 days before the surgical procedure and maintained for 24 h or for 7 
days. Doses: SRL (3 mg·kg-1·day-1, po) and CsA (3 mg·kg-1·day-1, sc). *P < 0.05 compared to the sham group; +P < 0.05 compared to 
the ischemia group (ANOVA followed by the Student-Newman-Keuls post-test).
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Figure 3. Illustration showing the characteristics of the three 
scores used to evaluate acute tubular necrosis (arrows): score 
1 (lesions in ≤25% of the section), score 2 (lesions in 26-50% of 
the section), score 3 (lesions in >50% of the section).
This alteration was less pronounced in the I + CsA group 
and more pronounced in the ischemia group. On day 7, 
foci of ATN remained in groups I + CsA and I + SRL + CsA 
and no ATN was observed in the other groups (Table 4 
and Figure 3). 
Blood concentration of cyclosporin A
There was no significant difference in blood CsA con-
centration between I + CsA and I + SRL + CsA groups 24 
h after drug administration (298 ± 29 vs 304 ± 36 mg/dL; 
P > 0.05).
Discussion
SRL is an immunosuppressant with a specific mecha-
nism of action and negligible nephrotoxicity (22,23). In ad-
dition, SRL can synergize with other immunosuppressants 
such as calcineurin inhibitors without additional side effects. 
Because of these characteristics, there has been consider-
able interest in the use of SRL in organ transplantation and 
autoimmune diseases (23). In contrast to the direct tubular 
toxicity demonstrated for CsA (5), we found that SRL had 
no effect on isolated proximal tubules, either in normoxia 
or in hypoxia/reoxygenation injury. These results reinforce 
the idea that sirolimus has no direct nephrotoxicity. In ad-
dition, the combination of SRL with CsA did not enhance 
the direct tubular toxicity of CsA. This can be attributed 
to the difference in the intracellular activity of these two 
drugs, which distinguishes SRL from calcineurin inhibitors 
(1,5,23,24).
No significant change in GFR was observed at 24 h, 
probably due to the short-term ischemia associated with 
Table 4. Histomorphometric analysis in ischemic rats treated with 
sirolimus (I + SRL), cyclosporine A (I + CsA) and both (I + SRL 
+ CsA).
Sham Ischemia I + 
SRL
I + 
CsA
I + SRL + 
CsA
Score 1
24 h 50.0 33.4 60.0 66.6 50.0
7 days 100.0 50.0 85.7 57.1 28.6
Score 2
24 h 50.0 16.7 20.0 22.2 16.7
7 days 0 50.0 14.3 28.6 57.1
Score 3
24 h 0 50.0 20.0 11.2 33.3
7 days 0 0 0 14.3 14.3
Data are reported as percent. Score 1: ≤25% of the section was 
affected; Score 2: 26-50% of the section was affected; Score 3: 
>50% of the section was affected. All drugs were administered 
2 days before the surgical procedure and maintained for 24 h 
or for 7 days. Doses: SRL (3 mg·kg-1·day-1, po) and CsA (3 
mg·kg-1·day-1, sc).
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unilateral nephrectomy, which reduces acute renal insuf-
ficiency. The combination of SRL and CsA caused mild 
tubular injury demonstrated by the increased FENa at 24 h 
and the decreased urinary osmolality of the group treated 
only with CsA (Table 3). On day 7, only the I + CsA group 
presented tubular dysfunction and reduced GFR (Table 3), 
which was attenuated by the combination with SRL. This 
finding corroborates those of clinical studies that have 
shown that a combination of SRL with low doses of CsA 
has a beneficial effect on graft survival (25,26). However, 
experimental studies have yielded contradictory results 
(26,27). Burdmann et al. (27) demonstrated that there 
was an increase in enzymuria 14 days after CsA or FK506 
administration, which did not occur with SRL. Whiting et al. 
(28) showed that SRL and CsA together caused a significant 
increase in enzymuria and a reduction of GFR, both effects 
attributable to additive renal toxicity (29,30). Lieberthal et 
al. (15) demonstrated that recovery of renal function was 
delayed in rats treated with SRL on days 3 and 4 after 
40-min ischemia. Using a model of chronic nephrotoxic-
ity, Shihab et al. (30) found that SRL alone did not affect 
renal function, but SRL in combination with low doses of 
CsA presented a nephrotoxic effect, which was attributed 
to a greater TGF-β1 expression. In the present study, we 
observed tubular changes but no GFR alterations, sug-
gesting that SRL might have an initial toxic effect that was 
undetectable after 7 days of treatment, when its protective 
effect against CsA toxicity was observed.
At 24 h, hemodynamic alterations were observed in 
all groups submitted to ischemia (Table 3). This finding 
was probably due to vasoconstriction, a common event 
occurring immediately after ischemia, caused in part by 
the activation of the tubuloglomerular feedback. Vasocon-
striction can also be caused by increased basal vascular 
tone, by enhanced reactivity to vasoconstrictors or by the 
reduced vasodilator response observed in post-ischemic 
kidneys (25). Hemodynamic changes such as increased 
RVR and reduced RBF had reverted in all groups by day 
7, except in those receiving CsA. However, although RVR 
and RBF values did not revert in the I + SRL + CsA group, 
the GFR of this group was comparable to that of non-CsA 
groups (Table 3). Therefore, the GFR reduction observed 
in the I + CsA group might have been due to CsA-induced 
vasoconstriction. These acute effects of CsA have been 
described (28,31). Sabbatini et al. (32) demonstrated that 
immunosuppressant doses of CsA were toxic, whereas 
SRL, even at high doses, had a negligible effect on renal 
and glomerular dynamics. L’Azou et al. (31) demonstrated 
that CsA nephrotoxicity was mediated by mesangial cell 
contraction and a consequent decrease in the capillary filtra-
tion coefficient. We believe that the preserved GFR in the I 
+ SRL + CsA group was probably due to the SRL-induced 
increase in capillary filtration coefficient, since glomerular 
filtration was restored despite RBF reduction. Our findings 
agree with other studies, which have reported that the com-
bination of CsA and SRL may have a beneficial, synergistic 
immunosuppressive effect (without additional nephrotoxic 
effects), which might result in improved post-transplant 
renal function (9,10,26,33). The protection provided by SRL 
against CsA nephrotoxicity in ischemia/reperfusion injury 
cannot be attributed to reduced blood concentrations of 
CsA since blood levels of CsA were comparable between 
groups I + CsA and I + SRL + CsA. Similar findings have 
been reported by Whiting et al. (28).
Foci of ATN were found in all groups after 24 h, although 
less pronounced in the CsA group. Histological analysis 
performed on day 7 showed partial recovery from ATN, 
although less pronounced in I + CsA and I + SRL + CsA 
groups. No correlation was observed between histologi-
cal and functional findings in the present study. However, 
score 1 and score 2 lesions were more prevalent in the 
groups receiving CsA (Table 4). It is also noteworthy that 
the tubular vacuolization, nephrocalcinosis, tubular atrophy, 
and interstitial fibrosis observed in another study, in which 
CsA was administered for 15 days or more (2), were not 
observed in the present study.
In conclusion, SRL had no direct toxic effects and did 
not enhance hypoxia/reoxygenation injury or CsA toxicity 
in isolated renal proximal tubules. SRL also did not affect 
GFR after ischemia and prevented CsA-induced toxicity in 
the ischemic kidney. 
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